FENC Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -5.12% compared to Fennec Pharmaceuticals, Inc.'s net margin of -255.85%. Fennec Pharmaceuticals, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Fennec Pharmaceuticals, Inc. has a consensus price target of $14.60, signalling upside risk potential of 91.1%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Fennec Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Fennec Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Fennec Pharmaceuticals, Inc. has a beta of 0.752, which suggesting that the stock is 24.803% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Fennec Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Fennec Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Fennec Pharmaceuticals, Inc. quarterly revenues are $12.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Fennec Pharmaceuticals, Inc.'s net income of -$638K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Fennec Pharmaceuticals, Inc.'s price-to-earnings ratio is 139.25x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fennec Pharmaceuticals, Inc. is 5.45x versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -5.12% compared to Fennec Pharmaceuticals, Inc.'s net margin of --. Fennec Pharmaceuticals, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Fennec Pharmaceuticals, Inc. has a consensus price target of $14.60, signalling upside risk potential of 91.1%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Fennec Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Fennec Pharmaceuticals, Inc..

Fennec Pharmaceuticals, Inc. has a beta of 0.752, which suggesting that the stock is 24.803% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Fennec Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fennec Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Fennec Pharmaceuticals, Inc. quarterly revenues are $12.5M, which are larger than Palatin Technologies quarterly revenues of --. Fennec Pharmaceuticals, Inc.'s net income of -$638K is higher than Palatin Technologies's net income of --. Notably, Fennec Pharmaceuticals, Inc.'s price-to-earnings ratio is 139.25x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fennec Pharmaceuticals, Inc. is 5.45x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -5.12% compared to Fennec Pharmaceuticals, Inc.'s net margin of --. Fennec Pharmaceuticals, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Fennec Pharmaceuticals, Inc. has a consensus price target of $14.60, signalling upside risk potential of 91.1%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than Fennec Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Fennec Pharmaceuticals, Inc..

Fennec Pharmaceuticals, Inc. has a beta of 0.752, which suggesting that the stock is 24.803% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Fennec Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fennec Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Fennec Pharmaceuticals, Inc. quarterly revenues are $12.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Fennec Pharmaceuticals, Inc.'s net income of -$638K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Fennec Pharmaceuticals, Inc.'s price-to-earnings ratio is 139.25x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fennec Pharmaceuticals, Inc. is 5.45x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging Corp. has a net margin of -5.12% compared to Fennec Pharmaceuticals, Inc.'s net margin of 5.33%. Fennec Pharmaceuticals, Inc.'s return on equity of -- beat Varex Imaging Corp.'s return on equity of -13.35%.

Fennec Pharmaceuticals, Inc. has a consensus price target of $14.60, signalling upside risk potential of 91.1%. On the other hand Varex Imaging Corp. has an analysts' consensus of $17.20 which suggests that it could grow by 42.62%. Given that Fennec Pharmaceuticals, Inc. has higher upside potential than Varex Imaging Corp., analysts believe Fennec Pharmaceuticals, Inc. is more attractive than Varex Imaging Corp..

Fennec Pharmaceuticals, Inc. has a beta of 0.752, which suggesting that the stock is 24.803% less volatile than S&P 500. In comparison Varex Imaging Corp. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.269%.

Fennec Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fennec Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Varex Imaging Corp. pays out -- of its earnings as a dividend.

Fennec Pharmaceuticals, Inc. quarterly revenues are $12.5M, which are smaller than Varex Imaging Corp. quarterly revenues of $228.9M. Fennec Pharmaceuticals, Inc.'s net income of -$638K is lower than Varex Imaging Corp.'s net income of $12.2M. Notably, Fennec Pharmaceuticals, Inc.'s price-to-earnings ratio is 139.25x while Varex Imaging Corp.'s PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fennec Pharmaceuticals, Inc. is 5.45x versus 0.63x for Varex Imaging Corp.. Usually stocks with elevated PS ratios are considered overvalued.